Preparation and Pharmacokinetics of Docetaxel Based on Nanostructured Lipid Carriers

Xiang Li,Dongkai Wang,Jing Zhang,Weisan Pan

DOI: https://doi.org/10.1211/jpp/61.11.0007

2009-01-01

Journal of Pharmacy and Pharmacology

Abstract:Objectives This study describes the preparation and pharmacokinetics of docetaxel based on freeze‐dried nanostructured lipid carriers (NLCs).

What problem does this paper attempt to address?

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Donghua Liu,Zhihong Liu,Lili Wang,Cai Zhang,Na Zhang

DOI: https://doi.org/10.1016/j.colsurfb.2011.02.038

2011-01-01

Abstract:The aim of this study was to design docetaxel-loaded nanostructured lipid carriers (DTX-NLC) to reduce toxicity and improve therapeutic efficacy. Docetaxel-loaded nanostructured lipid carriers (DTX-NLC) were prepared by the modified film ultrasonication–dispersion method. The DTX-NLC were characterized by particle size distribution, zeta potential and entrapment efficiency. In vitro cytotoxicity of DTX-NLC was evaluated by MTT assay against three human cancer cell lines and one murine malignant melanoma (B16). AnnexinV-FITC kit was used to measure the percentage of apoptosis induced by Duopafei® or DTX-NLC. In vivo anti-tumor efficacy was evaluated in Kunming mice bearing murine malignant melanoma (B16). Compared with Duopafei®, DTX-NLC revealed more cytotoxicity against A549 cells by inducing more apoptosis and more G2/M arrest. The inhibition rates of Duopafei®, DTX-NLC (10mg/kg) and DTX-NLC (20mg/kg) were 42.74%, 62.69% and 90.36%, respectively, indicating that DTX-NLC could more effectively inhibit tumor growth. The results of the body weight variations of mice also showed that compared with Duopafei®, DTX-NLC had lower toxicity during the therapeutic procedure. These results suggest that DTX-NLC may be a promising drug delivery system for cancer therapy. To our knowledge, this was the first report about DTX-NLC for murine malignant melanoma treatment.
Preparation and studies of docetaxel proliposome

Ying Zhu,Shiyao Luo,Yuejian Chen,Faisal Raza,Han Han,Zhewei Huang,Yiping Li,Liang Ge

DOI: https://doi.org/10.1166/mex.2019.1563

2019-01-01

Materials Express

Abstract:The taxanes, paclitaxel and docetaxel, are anticancer agents used in clinical trials against ovarian carcinoma, breast, lung and head/neck cancer. Docetaxel, more soluble than paclitaxel in water, is formulated using Tween 80 and ethanol. Tween 80, albeit less toxic than Cremophor EL, may be responsible of some toxic effects. To eliminate these vehicles and improve the drug's antitumor efficacy, taxanes have been incorporated in liposomes, however the stability of the common liposomes was poor. We have prepared a well-characterized novel lyophilized liposome-based docetaxel formulation that is sterile and easy-to-use. Of the several formulations examined, docetaxel-liposomes composed of ePC/CHOL 15:3 and co-surfactant poloxamer188/ePC/3:5 were chosen for further studies. This composition was found to give more stable liposomes than other formulations. It gave 95% entrapment efficiency and particle size of 200 nm after lyophilization. The pharmacokinetic parameters intravenously administration to the rats were determined and compared with those of commercial docetaxel formulations. Encapsulation of docetaxel in proliposomes produced marked differences over the commercial preparations with an increased Cmax, prolonged elimination half-life, and an increased value for Area Under Curve (AUC). The obtained values for mean residence time (MRT) indicated that docetaxel remains longer for liposomal formulation. The docetaxel proliposome (PRDL) was more effective than docetaxel injection (DXL-INJ) and plain docetaxel liposome (PDL) in the high, medium and low docetaxel dose trials.
Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery.

Xiucong Fan,Jinjin Chen,Qi Shen

DOI: https://doi.org/10.1016/j.ijpharm.2013.10.036

IF: 6.51

2013-01-01

International Journal of Pharmaceutics

Abstract:Docetaxel (DTX) proved one of the most effective active pharmaceutical ingredients (APIs) for the treatment of cancers. However, in respect of its low solubility and high lipophilic property, nicotinamide (NCT) was chosen as the co-former to form the docetaxel–nicotinamide complex to handle the drawbacks. As was analyzed by Fourier Transform Infrared spectrometer, thermal analysis and saturated solubility, the complex proved stable. Then, docetaxel–nicotinamide complex nanostructured lipid carriers (DN-NLCs) were prepared by emulsion-evaporation at low temperature method. The average drug entrapment efficiency, particle size and drug loading of docetaxel-NLCs (D-NLCs) and DN-NLCs were 81.41–79.48%, 61.45–59.48nm and 1.60–1.63%, respectively. The physicochemical characteristics of nanoparticles were valued by transmission electron microscope and Powder X Ray Diffraction. The in vitro drug-release profile of nanoparticle formulations fitted the Weibull dynamic equation. The skin permeability test was performed by Vertical Franz-type diffusion cells. It demonstrated that DN-NLCs transported drugs more easily than D-NLCs. Confocal Laser Scanning Microscopy observation showed DN-NLCs permeated more effectively than D-NLCs. In vivo study demonstrated that DN-NLCs maintained most in the skin. These results suggest that the DN-NLCs can be a useful method to increase skin permeation of docetaxel.
Preparation and Characterization of a Nanostructured Lipid Carrier for a Poorly Soluble Drug

Yiyin Chen,Xiaomin Yang,Lin Zhao,Laszlo Almasy,Vasil M. Garamus,Regine Willumeit,Aihua Zou

DOI: https://doi.org/10.1016/j.colsurfa.2014.04.032

2014-01-01

Abstract:The aim of this study was to prepare a stable nanostructured lipid carrier (NLC) with biocompatible lipids and surfactants (Pluronic F68 and Cremophor EL) by high-pressure homogenization (HPH). Surface tension measurements were used to choose the suitable ratio between Pluronic F68 and Cremophor EL. Hydrophobic anticancer drug docetaxel (DTX) was used as an active pharmaceutical ingredient (API). The mean particle size of docetaxel loaded nanostructured lipid carrier (DTX-NLC), as determined by dynamic light scattering (DLS), was between 120 nm and 250 nm during the storage period of 30 days, with the entrapment efficiency decreasing from (60.5 +/- 5.0)% to (55.3 +/- 4.5)%, while zeta potential was slightly changed from (-43.19 +/- 3.6) mV to (-40.12 +/- 4.3) mV. Transmission electron microscopy (TEM) showed that some of DTX-NLCs have elongated shape. Small angle neutron scattering (SANS) demonstrated that DTX-NLC in solution contained dense core with perfectly smooth surface, while blank NLC had dense core but rough surface. The blank NLC and DTX-NLC showed cubic crystalline structure according to small angle X-ray scattering (SAXS). Wide angle X-ray diffraction (XRD) showed that adding of DTX increased the crystallinity of the NLC. Cytotoxicity was studied by MTT assay against Hela cells. The data suggested that blank NLC was biocompatible with HeLa cells while the DTX-NLC was more cytotoxic than pure DTX at the same drug concentration. DTX-NLC could be taken up into the cells more than pure DTX, which could be attributed to the better solubility of DTX after loading into NLC. (C) 2014 Elsevier B.V. All rights reserved.
Enhanced Oral Bioavailability of Docetaxel by Lecithin Nanoparticles: Preparation, in Vitro, and in Vivo Evaluation

Kaili Hu,Shan Cao,Fuqiang Hu,Jianfang Feng

DOI: https://doi.org/10.2147/ijn.s32880

IF: 7.033

2012-01-01

International Journal of Nanomedicine

Abstract:The aim of this research work was to investigate the potential of lecithin nanoparticles (LNs) in improving the oral bioavailability of docetaxel. Docetaxel-loaded LNs (DTX-LNs) were prepared from oil-in-water emulsions and characterized in terms of morphology, size, zeta potential, and encapsulation efficiency. The in vitro release of docetaxel from the nanoparticles was studied by using dialysis bag method. Caco-2 cell monolayer was used for the in vitro permeation study of DTX-LNs. Bioavailability studies were conducted in rats and different pharmacokinetic parameters were evaluated after oral administration of DTX-LNs. The results showed that DTX-LNs had a mean diameter of 360 ± 8 nm and exhibited spherical shape with smooth surface under transmission electron microscopy. The DTX-LNs showed a sustained-release profile, with about 80% of docetaxel released within 72 hours. The apical to basolateral transport of docetaxel across the Caco-2 cell monolayer from the DTX-LNs was 2.14 times compared to that of the docetaxel solution (0.15 × 10⁻⁵ ± 0.016 × 10⁻⁵ cm/second versus 0.07 × 10⁻⁵ ± 0.003 × 10⁻⁵ cm/second). The oral bioavailability of the DTX-LNs was 3.65 times that of docetaxel solution (8.75% versus 2.40%). These results indicate that DTX-LNs were valuable as an oral drug delivery system to enhance the absorption of docetaxel.
Current Development in Nanoformulations of Docetaxel

Qi Tan,Xiuju Liu,Xinyu Fu,Qilu Li,Jinfeng Dou,Guangxi Zhai

DOI: https://doi.org/10.1517/17425247.2012.696606

2012-01-01

Expert Opinion on Drug Delivery

Abstract:Introduction: Docetaxel (DTX) has been proven as one of the most important cytotoxic agents, and its clinical efﬁcacy against many cancers is superior to paclitaxel. DTX in commercial formulation contains the non-ionic surfactant Tween 80 (polysorbate 80) and 13% ethanol; the side effects caused by DTX and the solvent have considerably limited its clinical use. In recent decades, the emergence of nanoformulations provides new modes of actions in DTX. Many nano-sized carriers can help DTX transport through leaky tumor capillary fenestrations into the tumor cells. Moreover, these particles can be modified for binding to specific sites such as cancer cell membranes, cytoplasmic or nuclear receptors. Areas covered: The authors focus on nanoformulations related to DTX delivery, covering their preparation, physicochemical properties and the in vitro and in vivo actions against tumor cells. The challenges involved in the development of nanoformulations for DTX are also discussed. Expert opinion: Although nanoformulations such as liposome, micelle, nanoparticle, nanoemulsion greatly improve the solubility, activity and distribution of DTX in vivo, significant hurdles remain concerning aspects of nanoformulations such as quality control, physicochemical stability, storage conditions, large-scale production and controlled manufacture technology, in vivo metabolism, excretion, acute and chronic toxicity, etc. In-depth studies in these areas are essential to making DTX nanoformulations applicable in clinic and commercially available viable.
Current development in nanoformulations of docetaxel.

Qi Tan,Xiuju Liu,Xinyu Fu,Qilu Li,Jinfeng Dou,Guangxi Zhai

DOI: https://doi.org/10.1517/17425247.2012.696606

2012-01-01

Expert Opinion on Drug Delivery

Abstract:Introduction: Docetaxel (DTX) has been proven as one of the most important cytotoxic agents, and its clinical efcacy against many cancers is superior to paclitaxel. DTX in commercial formulation contains the non-ionic surfactant Tween 80 (polysorbate 80) and 13% ethanol; the side effects caused by DTX and the solvent have considerably limited its clinical use. In recent decades, the emergence of nanoformulations provides new modes of actions in DTX. Many nano-sized carriers can help DTX transport through leaky tumor capillary fenestrations into the tumor cells. Moreover, these particles can be modified for binding to specific sites such as cancer cell membranes, cytoplasmic or nuclear receptors. Areas covered: The authors focus on nanoformulations related to DTX delivery, covering their preparation, physicochemical properties and the in vitro and in vivo actions against tumor cells. The challenges involved in the development of nanoformulations for DTX are also discussed. Expert opinion: Although nanoformulations such as liposome, micelle, nanoparticle, nanoemulsion greatly improve the solubility, activity and distribution of DTX in vivo, significant hurdles remain concerning aspects of nanoformulations such as quality control, physicochemical stability, storage conditions, large-scale production and controlled manufacture technology, in vivo metabolism, excretion, acute and chronic toxicity, etc. In-depth studies in these areas are essential to making DTX nanoformulations applicable in clinic and commercially available viable.
Docetaxel-Loaded-Lipid-Based-Nanosuspensions (Dtx-Lns): Preparation, Pharmacokinetics, Tissue Distribution and Antitumor Activity

Lili Wang,Zhihong Liu,Donghua Liu,Chunxi Liu,Zhang Juan,Na Zhang

DOI: https://doi.org/10.1016/j.ijpharm.2011.04.023

IF: 6.51

2011-01-01

International Journal of Pharmaceutics

Abstract:The purpose of the study was to design lipid-based-nanosuspensions (LNS) for Docetaxel (DTX) without Tween 80 for clinical intravenous administration (i.v.). DTX-LNS were prepared by high pressure homogenization method, and then lyophilization was carried out to improve the stability. The physical-chemical properties in terms of particle size, size distribution, zeta potential and morphology were evaluated, respectively. The in vitro cytotoxic activity was assessed by MTT against SKOV-3 and malignant melanoma B16 cells. The in vivo pharmacokinetics, tissue distribution as well as antitumor efficacy were investigated in B16 melanoma-bearing Kunming mice. The particle size and zeta potential of DTX-LNS were (200.0 ± 3.42)nm and (-11.15 ± 0.99)mV, respectively. Compared with Duopafei, it was shown that DTX-LNS exhibited higher antitumor efficacy by reducing tumor volume (P<0.05) and increasing survival rate in B16 melanoma-bearing mice and strongly reduced the anticancer drug toxicity. The results of biodistribution studies clearly indicated the superiority of DTX-LNS to Duopafei in increasing the accumulation of DTX within tumor and the organs rich in macrophages (liver, lungs and spleen), while, the drug concentration in heart and kidney decreased. Together these results suggested that DTX-LNS could effectively inhibit tumor growth, reduce toxicity during the therapeutic procedure and hold the potential to be an appropriate choice for the clinical administration of DTX.
Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy

Florentina-Iuliana Cocoș,Valentina Anuța,Lăcrămioara Popa,Mihaela Violeta Ghica,Mihaela-Alexandra Nica,Mirela Mihăilă,Radu Claudiu Fierăscu,Bogdan Trică,Cristian Andi Nicolae,Cristina-Elena Dinu-Pîrvu

DOI: https://doi.org/10.3390/pharmaceutics16070960

IF: 6.525

2024-07-19

Pharmaceutics

Abstract:This study focuses on the design, characterization, and optimization of nanostructured lipid carriers (NLCs) loaded with docetaxel for the treatment of skin cancer. Employing a systematic formulation development process guided by Design of Experiments (DoE) principles, key parameters such as particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency were optimized to ensure the stability and drug-loading efficacy of the NLCs. Combined XRD and cryo-TEM analysis were employed for NLC nanostructure evaluation, confirming the formation of well-defined nanostructures. In vitro kinetics studies demonstrated controlled and sustained docetaxel release over 48 h, emphasizing the potential for prolonged therapeutic effects. Cytotoxicity assays on human umbilical vein endothelial cells (HUVEC) and SK-MEL-24 melanoma cell line revealed enhanced efficacy against cancer cells, with significant selective cytotoxicity and minimal impact on normal cells. This multidimensional approach, encompassing formulation optimization and comprehensive characterization, positions the docetaxel-loaded NLCs as promising candidates for advanced skin cancer therapy. The findings underscore the potential translational impact of these nanocarriers, paving the way for future preclinical investigations and clinical applications in skin cancer treatment.

pharmacology & pharmacy
Advances in nano-drug delivery systems for docetaxel

WANG Li-li,HOU Jian-ling,SUN Xiao-li,ZHANG Na

2010-01-01

Abstract:Docetaxel(DTX) is widely used in the treatment of ovarian cancer,breast cancer,lung cancer and other tumors,which belongs to the taxoid family.Clinical application of this drug is limited by its poor aqueous solubility,low bioavailability and toxicity.Nano-drug delivery systems have gained much attention as novel carriers for anticancer drugs,primarily due to the unique properties of nanocarriers including to enhance the solubility of poorly water soluble drug,to reduce the toxicity and to increase the target efficiency of the drug to specific tumor tissues.A variety of docetaxel loaded nanocarriers such as liposome,nanoemulsion,nanoparticles,micelles,etc.are already under research and show a good prospect of application.This paper reviews the advances in the nano-drug delivery systems for docetaxel.
How Nanotechnology Can Enhance Docetaxel Therapy

Li Zhang,Na Zhang

DOI: https://doi.org/10.2147/ijn.s46921

IF: 7.033

2013-01-01

International Journal of Nanomedicine

Abstract:Docetaxel has been recognized as one of the most efficient anticancer drugs over the past decade; however, its poor water solubility and systemic toxicity have greatly limited its clinical application. In recent decades, the emergence of nanotechnology has provided new drug delivery systems for docetaxel, which can improve its water solubility, minimize the side effects and increase the tumor-targeting distribution by passive or active targeting. This review focuses on the research progress in nanoformulations related to docetaxel delivery - such as polymer-based, lipid-based, and lipid-polymer hybrid nanocarriers, as well as inorganic nanoparticles - addressing their structures, characteristics, preparation, physicochemical properties, methods by which drugs are loaded into them, and their in vitro and in vivo efficacies. Further, the targeted ligands used in the docetaxel nanoformulations, such as monoclonal antibodies, peptides, folic acid, transferrin, aptamers and hyaluronic acid, are described. The issues to overcome before docetaxel nanoformulations can be used in clinical and commercial applications are also discussed.
Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes.

Ge Liang,Zhu Jia-Bi,Xiong Fei,Ni Bin

DOI: https://doi.org/10.1211/jpp.59.5.0006

2007-01-01

Journal of Pharmacy and Pharmacology

Abstract:The objective of this work was to investigate the preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. To decrease toxic effects and improve antitumour efficacy of the drug, clocetaxel has been incorporated in liposomes; the formulation, stability and pharmacokinetics of plain clocetaxel liposomes (PDLs), PEGylated clocetaxel liposomes (PEGDLs) and N-palmitoyl chitosan anchored clocetaxel liposomes (NDLs) were compared. NDL was more stable than PDL and PIEGDL in-vitro, especially in the presence of serum at 37 degrees C. The concentration of clocetaxel in the plasma of rats after intravenous administration of clocetaxel injection, PDL, PEGDL and NDL was studied by RP-HPLC. The pharmacokinetic behaviour of clocetaxel injection, PDL, PEGDL and NDL were significantly different. These findings suggest that anchored liposomes could increase the stability of clocetaxel in-vivo, as compared with plain liposomes, but the improvement was not more significant than PEGylated liposomes. N-Palmitoyl chitosan as a new polymeric membrane to anchor liposome was useful to stabilize liposomes containing anti-tumour drug.
Preparation, Characterization, and in Vitro Evaluation of Docetaxel-Loaded Poly(lactic Acid)-Poly(ethylene Glycol) Nanoparticles for Parenteral Drug Delivery.

Donghua Liu,Lili Wang,Zhihong Liu,Cai Zhang,Na Zhang

DOI: https://doi.org/10.1166/jbn.2010.1160

2010-01-01

Journal of Biomedical Nanotechnology

Abstract:The aim of this study was to develop a suitable drug delivery system without Tween 80 and design docetaxel (DTX)-loaded PLA-PEG nanoparticles to improve solubility and decrease side effect of docetaxel. DTX-loaded PLA-PEG nanoparticles were prepared by modified solvent volatilixation method and characterized by particle size distribution, zeta potential and entrapment efficiency. The morphology of DTX loaded PLA-PEG nanoparticles was approximately spherical. The mean diameter and zeta potential of freeze-dried PLA-PEG nanoparticles were 205 +/- 8.1 nm and -24.17 +/- 2.20 mV, respectively. The average entrapment efficiency and drug loading of freeze-dried DTX-loaded PLA-PEG nanoparticles were 91.83 +/- 1.28% and 8.17 +/- 0.35%, respectively. The in vitro release showed that the release from DTX loaded PLA-PEG nanoparticles was slower than from Duopafei and followed the Weibull equation. Cytotoxicity of Duopafei and DTX loaded PLA-PEG nanoparticles was evaluated. Compared with Duopafei, DTX-loaded PLA-PEG nanoparticles showed similar cytotoxicity against three human cancer cell lines and lower toxicity on human normal hepatocellular HL-7702 cells. The apoptosis was detected and measured with Hoechst 33342 and AnnexinV-FITC kit. Compared with Duopafei, DTX-loaded PLA-PEG nanoparticles revealed similar cytotoxicity against A549 cells by inducing similar apoptosis. These results indicated that the PLA-PEG nanoparticles obtained in this study could potentially be exploited as a carrier without Tween 80, which improved drug solubility and decrease side effect of docetaxel.
A Novel Lipid-Based Nanomicelle of Docetaxel: Evaluation of Antitumor Activity and Biodistribution

Mingshu Ma,Yanli Hao,Nan Liu,Zhe Yin,Lan Wang,Xingjie Liang,Xiaoning Zhang

DOI: https://doi.org/10.2147/ijn.s29827

IF: 7.033

2012-01-01

International Journal of Nanomedicine

Abstract:Purpose: A lipid-based, nanomicelle-loaded docetaxel (M-DOC) was designed and characterized. Optical imaging was employed to evaluate the pharmacokinetics and antitumor efficacy of docetaxel in vivo.Materials and methods: The M-DOC was prepared using the emulsion-diffusion method. Transmission electron microscopy and dynamic light scattering were used to assess the morphology and particle size of the M-DOC. Critical micelle concentrations, their stability under physiological conditions, and their encapsulation efficiency - as measured by high-performance liquid chromatography - were assessed. Pharmacological features were evaluated in two different animal models by comparing M-DOC treatments with docetaxel injections (I-DOC). Bioluminescence imaging was used to assess antitumor activity and docetaxel distribution in vivo, using nude mice injected with luciferase-expressing MDA-MB-231 human breast tumor cells. In addition, animals injected with B16 melanoma cells were used to measure survival time and docetaxel distribution.Results: The M-DOC was prepared as round, uniform spheres with an effective diameter of 20.8 nm. The critical micelle concentration of the original emulsion was 0.06%. Satisfactory encapsulation efficiency (87.6% +/- 3.0%) and 12-hour stability were achieved. Xenograft results demonstrated that the M-DOC was more effective in inhibiting tumor growth, without significantly changing body weight. Survival was prolonged by 12.6% in the M-DOC group. Tumor growth inhibitory rates in the M-DOC and I-DOC groups were 91.2% and 57.8% in volume and 71.8% and 44.9% in weight, respectively. Optical bioluminescence imaging of tumor growths yielded similar results. Area under the curve((0-6 hour)) levels of docetaxel in blood and tumors were significantly higher in the M-DOC group (15.9 +/- 3.2 mu g/mL(-1), 601.1 +/- 194.5 mu g/g(-1)) than in the I-DOC group (7.2 +/- 1.7 mu g/mL(-1), 357.8 +/- 86.2 mu g/g(-1)). The fluorescent dye 1,1-dioctadecyl-3,3,3,3'-tetramethylindotricarbocyanine iodide mimicked M-DOC in optical imaging, and accumulated more in tumors in comparison with I-DOC.Conclusion: These results suggest that the lipid-based nanomicelle system was effective in inhibiting tumor growth, with little toxicity. Moreover, we have developed a noninvasive optical imaging method for antitumor drug evaluation, which merits further analysis for potential clinical applications.
Preparation and evaluation of docetaxel-loaded albumin nanoparticles for intravenous administration

Yi-Bo Wang,Jian-Cheng Wang,Meng Meng,Hua Zhang,Qiang Zhang

DOI: https://doi.org/10.5246/jcps.2010.03.030

2010-01-01

Abstract:Docetaxel (DTX) was incorporated into albumin nanoparticles to form the docetaxel loaded nanoparticles (DTX-NPs) with a high-pressure homogenization method. The purpose of this procedure was to improve the solubility, stability and biocompatibility of DTX. In our study, particle size, zeta potential, size distribution, and encapsulation efficiency were investigated. The crystalloid state of DTX in nanoparticles was further determined by the X-ray diffraction technique. The hemolysis rate, pharmacokinetics and pharmacodynamics of the DTX-NPs were analyzed and compared with the injectable docetaxel solution (DTX-Sol), which was fabricated according to the formulation of the commercial Taxotere(R). It demonstrated that the DTX-NPs were prepared successfully with these properties, including the (193±4) nm size, (-30 ±1) mV zeta potential and 69% ± 2% encapsulation efficiency. Higher stability was achieved in the lyophilized nanoparticles compared to that in the nanoparticle suspension. Furthermore, less hemolysis effect was observed in the DTX-NPs than that in the DTX-Sol. The pharmacokinetic and pharmacodynamic behaviors of the DTX-NPs were similar as that of DTX-Sol based on the in vivo experiments. In conclusion, albumin nanoparticles may act as a useful and safe carrier for DTX.
Preparation and Evaluation of Lipid Emulsified Docetaxel-Loaded Nanoparticles.

Fang Zhang,Minglu Chang,Yanna Yu,Yongchun Zhang,Guangpu Liu,Ting Wei,Tiantian Zuo,Yuanyuan Guan,Guimei Lin,Zhongxi Zhao

DOI: https://doi.org/10.1111/jphp.12472

2015-01-01

Journal of Pharmacy and Pharmacology

Abstract:ObjectivesLipid emulsified nanoparticles (LPNPs) have been developed to load anticancer drug docetaxel (DTX) in this work.MethodsWe evaluated DTX-loaded lipid emulsified nanoparticles (DTX-LPNPs) in vitro compared with the conventional nanoparticles (DTX-NPs). The newly developed formulation was compared with DTX-NPs in terms of physicochemical properties and in-vitro efficacy.Key findingsThese two formulations had similar physicochemical properties in our results. And it has been proven that phosphatidylethanolamine had higher emulsification efficiency (20-fold of polyvinyl alcohol) in the same preparation procedure. The in-vitro release of DTX from DTX-LPNPs showed burst release initially and then followed by a sustained release, which prolonged the half time. The cytotoxicity test indicated that the DTX-LPNPs were more effective against tumour growth, and the IC50 of Duopafei, DTX-NPs and DTX-LPNPs for the inhibition of human lung cancer A549 cells at 48h (n=3) were found to be 3.530.43, 1.15 +/- 0.06 and 0.55 +/- 0.08m, respectively. The evaluation of the cellular uptake showed that DTX-LPNPs improved the drug delivery into cytoplasm compared with the commercial product Duopafei and DTX-NPs.ConclusionsDTX-LPNPs may be a promising formulation for cancer therapy.
A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation

Yuchao Chen,Jing Chen,Yi Cheng,Lihua Luo,Pinjing Zheng,Yidan Tong,Zhao Li

DOI: https://doi.org/10.3109/08982104.2016.1158185

2016-03-31

Journal of Liposome Research

Abstract:OBJECTIVES: In this study, an improved lyophilized PEGylated liposomal formulation of docetaxel (DOC) has been developed.METHODS: PEGylated docetaxel liposome (PL-DOC) was prepared by thin-film evaporation method and lyophilization. The effect of various components of the lipids and their compatibility with DOC on the entrapment efficiency (EE) of liposome was investigated. The lyophilized PL-DOC was characterized by morphology, particle size, zeta potential, EE, release in vitro and stability. Pharmacokinetics and biodistribution in vivo of lyophilized PL-DOC were also investigated.RESULTS: The optimal liposome formulation was egg phosphatidylcholine (EPC):cholesterol (CH):DSPE-PEG2000:DOC = 56:40:4:4 (molar ratio). Sucrose and mannitol were chosen as cryoprotectant in the lyophilization (cryoprotectant-to-lipid (C/L) mass ratio = 8:1). The size of lyophilized PL-DOC was 152.3 ± 1.0 nm with negative charge and the EE was 89.75 ± 1.79%. Compared with nonlyophilized PL-DOC, the lyophilized PL-DOC was more stable at 4 °C for six months. The lyophilized PL-DOC also showed the good stability after reconstituted by 5% glucose injection. In vitro release study of PL-DOC showed that PL-DOC had a sustained release effect. After i.v. administration at the dose of 10 mg/kg in rats, a significant increase in the AUC0-∞, MRT0-∞ and t1/2 was observed in PL-DOC group compared with conventional docetaxel liposome (CL-DOC) and DOC injection (DOC-I) group. Biodistribution studies in mice showed that PL-DOC significantly decreased the uptake by the organs of mononuclear phagocytic system (MPS), such as liver and spleen, while prolonging the retention time of DOC in the plasma.CONCLUSION: Our PEGylated liposome formulation reported in this study could potentially produce viable clinical strategies for improved delivery of DOC for the treatment of human cancer.

pharmacology & pharmacy,biochemistry & molecular biology
Pharmacy Characters and Cytotoxic Activity of Docetaxel-Loaded Solid Lipid Nanoparticles with Different Sizes

GAO Wei,WENG Xiao-bin,HU Hai-yang,LIU Dan,JIN Yun-huan,CHEN Da-wei

DOI: https://doi.org/10.14066/j.cnki.cn21-1349/r.2010.12.007

2010-01-01

Abstract:Objective To prepare different sizes of docetaxel-loaded solid lipid nanoparticles,study their physico-chemical properties and investigate the effect of paricle size on drug release in vitro and cytotoxic effect.Methods The different sizes of docetaxel-loaded solid lipid nanoparticles were prepared by melt-emulsification-ultrasound method.The shape of SLN,entrapment efficiencies,particle size and Zeta potential were evaluated.The drug release and cytotoxicity in vitro were investigated among different sizes of docetaxel-loaded solid lipid nanoparticles.Results The results showed that the solid lipid nanoparticles were sphere and sphere-like.The particle sizes of the three kinds of docetaxel-loaded solid lipid nanoparticles were(83.7±8.4)nm,(162.7±11.9)nm,(232.1±26.4)nm,respectively.Zeta potential,entrapment efficiency and the cumulative release during 60 h of the DTX-SLN-83,DTX-SLN-162 and DTX-SLN-232 seperately were-24.19,-23.67,-23.19 mV;98.03%,97.84%,97.92%;86.34%,76.98%,67.14%,ND.After incubation for 24 h,the IC50 values of DTX-SLN-80,DTX-SLN-160,DTX-SLN-230,DTX solution and physical mixture were 3.36,6.20,9.74,13.15,12.92 mg·L-1;after incubation for 48 h,the IC50 values were 0.93,2.01,4.35,9.48,9.21 mg·L-1,after incubation for 72 h,the IC50 values were 0.30,0.91,1.67,7.36,7.82 mg·L-1.The results showd that the reduction of particle size could improve inhibitory action on tumor cells.Conclusions Using the melt-enmulsification-ultrasound method,the preparation of docetaxel-loaded solid lipid nanoparticles is highly feasible.The particle size of SLN has a significant influence on the drug release and cytotoxicity in vitro.There was a higher efficiency in killing MCF-7 cells in vitro and a faster drug release of docetaxel-loaded solid lipid nanoparticles with a decrease of particle size.
Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.

Sarah E Lee,Shawn F Bairstow,Jane O Werling,Mahesh V Chaubal,Lawrence Lin,Mary Ann Murphy,James P DiOrio,Jerome Gass,Barrett Rabinow,Xiaoen Wang,Yong Zhang,Zhijian Yang,Robert M Hoffman

DOI: https://doi.org/10.3109/10837450.2013.789911

2014-01-01

Pharmaceutical Development and Technology

Abstract:Objective: The purpose of this work was to prepare a stable paclitaxel nanosuspension and test it for potential use as a targeted chemotherapeutic. Different particle coatings were employed to assess their impact on cellular uptake in vitro. In vivo work was then performed to demonstrate efficacy in tumor-bearing mouse models. Materials and method: Paclitaxel nanosuspensions were prepared using a homogenization process and coated with excipients. Surface charge was measured by zeta potential, potency by high-performance liquid chromatography, and solubility using an in-line UV probe. Cellular uptake studies were performed via flow cytometry. In vivo experiments were performed to determine residence time, maximum tolerated dose, and the efficacy of paclitaxel nanosuspensions (Paclitaxel-NS). Results: A stable paclitaxel nanosuspension was prepared and coated with various excipients. Studies in mice showed that the nanosuspension was well-tolerated and at least as effective as the IV Taxol control in prolonging mouse survival in a head and neck cancer model as well as an ovarian cancer model with a lower overall drug dose than the traditional IV administration route. Conclusions: The paclitaxel nanosuspension is suitable for cellular uptake. The nanosuspension was effective in prolonging life in two separate xenograft orthotopic murine cancer models through two separate routes of administration.
Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation

Youssef Wahib Naguib,B. Leticia Rodriguez,Xinran Li,Stephen D. Hursting,Robert O. Williams,Zhengrong Cui

DOI: https://doi.org/10.1021/mp4006968

2014-03-12

Molecular Pharmaceutics

Abstract:Docetaxel (DCX) is a second generation taxane. It is approved by the U.S. Food and Drug Administration for the treatment of various types of cancer, including breast, non-small cell lung, and head and neck cancers. However, side effects, including those related to Tween 80, an excipient in current DCX formulations, can be severe. In the present study, we developed a novel solid lipid nanoparticle (SLN) composition of DCX. Trimyristin was selected from a list of high melting point triglycerides as the core lipid component of the SLNs, based on the rate at which the DCX was released from the SLNs and the stability of the SLNs. The trimyristin-based, PEGylated DCX-incorporated SLNs (DCX-SLNs) showed significantly higher cytotoxicity against various human and murine cancer cells in culture, as compared to DCX solubilized in a Tween 80/ethanol solution. Moreover, in a mouse model with pre-established tumors, the new DCX-SLNs were significantly more effective than DCX solubilized in a Tween 80/ethanol solution in inhibiting tumor growth without toxicity, likely because the DCX-SLNs increased the concentration of DCX in tumor tissues, but decreased the levels of DCX in major organs such as liver, spleen, heart, lung, and kidney. DCX-incorporated SLNs prepared with one or more high-melting point triglycerides may represent an improved DCX formulation.

pharmacology & pharmacy,medicine, research & experimental

Preparation and Pharmacokinetics of Docetaxel Based on Nanostructured Lipid Carriers

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Preparation and studies of docetaxel proliposome

Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery.

Preparation and Characterization of a Nanostructured Lipid Carrier for a Poorly Soluble Drug

Enhanced Oral Bioavailability of Docetaxel by Lecithin Nanoparticles: Preparation, in Vitro, and in Vivo Evaluation

Current Development in Nanoformulations of Docetaxel

Current development in nanoformulations of docetaxel.

Docetaxel-Loaded-Lipid-Based-Nanosuspensions (Dtx-Lns): Preparation, Pharmacokinetics, Tissue Distribution and Antitumor Activity

Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy

Advances in nano-drug delivery systems for docetaxel

How Nanotechnology Can Enhance Docetaxel Therapy

Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes.

Preparation, Characterization, and in Vitro Evaluation of Docetaxel-Loaded Poly(lactic Acid)-Poly(ethylene Glycol) Nanoparticles for Parenteral Drug Delivery.

A Novel Lipid-Based Nanomicelle of Docetaxel: Evaluation of Antitumor Activity and Biodistribution

Preparation and evaluation of docetaxel-loaded albumin nanoparticles for intravenous administration

Preparation and Evaluation of Lipid Emulsified Docetaxel-Loaded Nanoparticles.

A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation

Pharmacy Characters and Cytotoxic Activity of Docetaxel-Loaded Solid Lipid Nanoparticles with Different Sizes

Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.

Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation